The Wilcoxon test detected significant increases in BDNF levels from baseline to follow-up at 12 weeks in the intervention group; surprisingly, the levels of BDNF in the intervention group were similar to the control group without AD (Figure 2). Here, BDNF is linked to Alzheimer disease.